On September 27, 2023 Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, reported the presentation of 6 abstracts featuring its Lunit SCOPE suite at the upcoming SITC (Free SITC Whitepaper) 2023 (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2023) Annual Meeting, scheduled to take place from November 1 to November 5, in San Diego, California (Press release, Lunit, SEP 27, 2023, View Source [SID1234635473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This year’s posters span a spectrum of research, from predicting treatment outcomes in non-small cell lung cancer (NSCLC) to examining immune responses in breast cancer subtypes, utilizing the Lunit SCOPE suite.

The highlighted abstracts for SITC (Free SITC Whitepaper) 2023 include:

By analyzing the tumor microenvironment (TME) with Lunit SCOPE IO, one study explores the treatment response of non-small cell lung cancer (NSCLC) patients with EGFR mutations to immune checkpoint inhibitors (ICI) after acquiring resistance to EGFR tyrosine kinase inhibitors (TKI).
Lunit investigates the distribution of tumor-infiltrating lymphocytes (TIL) in triple-negative breast cancer (TNBC) subtypes and their association with driver mutations, shedding light on the complexities of TNBC treatment response.
Lunit delves into the relationship between methylation and cancer immunogenicity across multiple cancer types.
A study examines the influence of tumor fragmentation index (TFI) and fibroblast infiltration on inflammatory cytokines, and lymphocyte maturation in the tumor microenvironment across various carcinoma cancer types.
Lunit introduces an innovative approach to assess immune phenotype (IP) in tumor tissue using AI-powered analysis of PD-L1 IHC whole-slide images.
An additional presentation provides updated safety and efficacy results for a novel PD-1 (programmed cell death 1) agent, assessed by Lunit SCOPE IO.
"We are truly excited to showcase the capabilities of Lunit SCOPE products in assessing pathology data, improving our ability to identify responsive patients and understand cancer biology," said Brandon Suh, CEO of Lunit. "These study results promise to advance our understanding of the tumor microenvironment, paving the way for increasingly tailored and more effective cancer therapies."

Visit Lunit’s booth at SITC (Free SITC Whitepaper) 2023 at Booth 227 to learn more about these pioneering studies. To schedule a meeting with the Lunit team, please reach out to [email protected].

On September 27, 2023 Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, reported that it will present five programs at the 2023 Society of Immunology in Cancer Annual Meeting (SITC 2023) to be held in San Diego from November 1-5, 2023 (Press release, Antengene, SEP 27, 2023, View Source [SID1234635472]). As the world’s largest and most anticipated gathering in the field of immuno-oncology, the SITC (Free SITC Whitepaper) Annual Meeting is designed to promote scientific exchanges and cooperation for improving treatment outcomes for cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations feature five Antengene’s clinical and preclinical programs, including two clinical programs, the anti-CD24 monoclonal antibody ATG-031 and the PD-L1/4-1BB bispecific antibody ATG-101; two preclinical programs, the LILRB4 antagonist antibody ATG-034 and the GPRC5D/CD3 T-cell engager ATG-021; as well as the proprietary novel AnTenGager platform.

Details of those poster presentations
ATG-031(anti-CD24 monoclonal antibody)
Title: The preclinical characterization and translational research of ATG-031, a first-in-class humanized anti-CD24 antibody, for the treatment of solid tumors and hematological malignancies
Abstract: 1337
Date: November 3, 2023
Time: 9:00 AM – 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023

ATG-101(PD-L1/4-1BB bispecific antibody)
Title: Single-cell RNA sequencing reveals the positive feedback activation loop between T and dendritic cells induced by PD-L1x4-1BB bispecific antibody
Abstract: 1112
Date: November 4, 2023
Time: 9:00 AM – 8:30 PM Pacific Time; 0:00 AM – 11:30 AM Beijing Time, November 5, 2023

ATG-034 (LILRB4 antagonist antibody)
Title: Antibody targeting a specific epitope of LILRB4 induces potent ADCC/ADCP effect against leukemia cells
Abstract: 1391
Date: November 3, 2023
Time: 9:00 AM – 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023

ATG-021 (GPRC5D/CD3 T-cell engager)
Title: ATG-021, a novel 2+1 CD3-based T-cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine release
Abstract: 1191
Date: November 3, 2023
Time: 9:00 AM – 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023

AnTenGager Platform
Title: A novel "2+1" bispecific T cell engager platform, enables enhanced anti-tumor activity with reduced risk of CRS
Abstract: 1190
Date: November 4, 2023
Time: 9:00 AM – 8:30 PM Pacific Time; 0:00 AM – 11:30 AM Beijing Time, November 5, 2023

On September 27, 2023 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage research and development biotechnology company, reported several presentations to be unveiled at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain, including updated clinical data showcasing the feasibility and potential of the investigational combination of KRASG12C inhibitor, adagrasib with pembrolizumab in a study of treatment naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation (Press release, Mirati, SEP 27, 2023, View Source [SID1234635469]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Adagrasib is the first targeted KRASG12C inhibitor to show promising efficacy and early signs of durability in combination with an immune checkpoint inhibitor in the front line setting," said Alan Sandler, M.D. chief medical officer, Mirati Therapeutics. "Based on this compelling data, we plan to initiate enrollment in a global Phase 3 study in the fourth quarter evaluating adagrasib in combination with pembrolizumab in patients with KRAS G12C -mutated NSCLC with PD-L1 ≥50% with the hope of providing a better treatment option for these patients."

Presentation Title: KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Author: Marina C. Garassino
Abstract Number: 5053
Session: Proffered Paper session – NSCLC, metastatic
Presentation Date/Time: Fri, 10/20/23 16:40-16:50 CEST and 7:40-7:50 a.m. PST

Presentation Title: Adagrasib With or Without Cetuximab in Patients With KRASG12C-Mutated Colorectal Cancer (CRC): Analysis of Tumor Biomarkers and Genomic Alterations
Author: Meredith S. Pelster
Abstract Number: 3402
Session: Proffered Paper Session 1 – Gastrointestinal tumours, lower digestive
Presentation Date/Time: Sat, 10/21/2023 15:25-15:35 CEST and 6:25-6:35 a.m. PST

Presentation Title: SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Author: Hossein Borghaei
Abstract Number: 5049
Session: Proffered Paper session – NSCLC, metastatic
Presentation Date/Time: Fri, 10/20/23 16:00-16:10 CEST and 7:00-7:10 a.m. PST

Symposium: Near the conclusion ESMO (Free ESMO Whitepaper) 2023, Mirati is also sponsoring New Horizons in the Treatment of KRAS-Driven NSCLC and GI Cancers, an industry satellite symposium with Luis Paz-Ares, M.D., Ph.D. of Hospital Universitario 12 de Octubre, Aparna Parikh, M.D. of Mass General Cancer Center, Harvard Medical School and Keith Kerr, MB ChB, FRCPath, FRCPE of NHS Grampian. The symposium will discuss advances in targeting KRAS-driven NSCLC with a focus on the current status and future development of KRASG12C inhibitors, review the current status of targeted therapies for GI cancers and discuss the importance of timely molecular testing. The symposium will be held on October 23 from 13:00-14:30 CEST in the Valencia Auditorium, Hall 10, IFEMA Madrid.

On September 27, 2023 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported the presentation of interim data for the 2.15 to 12 mg target dose cohorts from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma (RRMM) (Press release, Harpoon Therapeutics, SEP 27, 2023, View Source [SID1234635468]). HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC) platform designed to recruit a patient’s immune cells to kill tumor cells. The data will be presented at the 20th International Myeloma Society (IMS) Annual Meeting in a poster presentation on September 28, 2023 in Athens, Greece.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of the data cut-off on August 12, 2023, 97 patients were treated with HPN217 across 14 dose escalation cohorts. The trial enrolled heavily pre-treated patients, of whom 65% were penta-drug exposed and 20% had been treated with BCMA-targeted agents.

In patients at the 12 mg target dose (N=19), a manageable tolerability profile was observed with low rates of CRS (16%, all G1-2) and no ICANS. Additionally, robust, early clinical activity (63% ORR) was seen. Treatment remains ongoing in 7 responders, while the median responder time on treatment continues to mature, currently 8.3 months (6.0-17.3+).

For the earlier 2.15 mg to 6 mg target dose cohorts, the median responder time on treatment was 21.8 months (10.4-27.5+), with several remaining on treatment with a sustained response.

"The early and durable responses at the 12 mg cohort of HPN217 in an RRMM patient population that has undergone extensive prior treatments are encouraging. The 63% overall response rate at the target dose level is strong, with many responses occurring early and deepening over time," said Luke Walker, M.D., Chief Medical Officer for Harpoon Therapeutics. "The low frequency of CRS and compelling efficacy continue to support late-stage development of HPN217 and its potential to become a differentiated option for patients."

Enrollment in dose escalation cohorts up to 24 mg is complete, and the maximum tolerated dose (MTD) has not been reached. Follow up is ongoing, and the evaluation of regimens will inform the choice of a recommended Phase 2 dose(s) at year end 2023.

The poster will be available on Harpoon’s website following the presentation.

For more details about the IMS Annual Meeting, please visit:
View Source;sortMenu=101000

On September 27, 2023 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, reported that two poster presentations highlighting the company’s Immuno-STAT platform and lead clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 38th Anniversary Annual Meeting (SITC 2023) (Press release, Cue Biopharma, SEP 27, 2023, View Source [SID1234635466]). The conference will be held in San Diego, California and virtually on November 1-5, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Title: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients
Abstract Number: 674
Presenter: Christine Chung, M.D., H. Lee Moffitt Cancer Center, Tampa, Fla. USA
Date: Saturday, November 4, 2023, Exhibit Halls A and B1, 9 a.m.–8:30 p.m. PDT

Title: A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
Abstract Number: 750
Presenter: Jennifer Eva Selfridge, M.D., Ph.D., University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Date: Saturday, November 4, 2023, Exhibit Halls A and B1, 9 a.m.–8:30 p.m. PDT

All posters will be available to conference attendees as virtual e-posters on the virtual meeting platform available November 3, 2023 at 9 am PDT through January 12, 2024. The posters will also be available on November 4, 2023 in the Investor & Media section of the Company’s website at www.cuebiopharma.com, under Scientific Publications and Presentations.

About the CUE-100 Series
The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient’s body. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing the potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.

About SITC (Free SITC Whitepaper)
Established in 1984, the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC (Free SITC Whitepaper) is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC (Free SITC Whitepaper) aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC (Free SITC Whitepaper) at sitcancer.org